Skip to main content
. 2017 Jul 21;31(12):1697–1706. doi: 10.1038/eye.2017.143

Table 1. Patient demographics and baseline characteristics.

Characteristicsa Main study
PED subgroup
Switched Treatment
Discontinued Treatment
  Ranibizumab cohort Aflibercept cohort P-value Ranibizumab cohort Aflibercept cohort P-value Ranibizumab cohort Aflibercept cohort Ranibizumab cohort Aflibercept cohort
Number of patients 2869 3630   208 176   847 442 882 697
Number (%b) of eyes 3350 (61.5%) 4300 (73.5%)   253 (7.6%) 203 (4.7%)   927 (17.0%) 484 (8.3%) 955 (17.5%) 785 (13.4%)
Agec (years), n (%)     <0.0001     0.0001        
 ≤70 209 (7.3%) 298 (8.2%)   10 (4.8%) 16 (9.1%)   91 (10.7%) 55 (12.4%) 61 (6.9%) 43 (6.2%)
 71–75 255 (8.9%) 382 (10.5%)   16 (7.7%) 22 (12.5%)   101 (11.9%) 45 (10.2%) 64 (7.3%) 62 (8.9%)
 76–80 413 (14.4%) 638 (17.6%)   30 (14.4%) 42 (23.9%)   135 (15.9%) 60 (13.6%) 133 (15.1%) 112 (16.1%)
 81–85 636 (22.2%) 863 (23.8%)   50 (24.0%) 29 (16.5%)   192 (22.7%) 105 (23.8%) 188 (21.3%) 159 (22.8%)
 86–89 604 (21.1%) 726 (20.0%)   34 (16.3%) 40 (22.7%)   159 (18.8%) 88 (19.9%) 169 (19.2%) 131 (18.8%)
 90+ 752 (26.2%) 723 (19.9%)   68 (32.7%) 27 (15.3%)   169 (20.0%) 89 (20.1%) 267 (30.3%) 190 (27.3%)
 Min 33.0 38.0   63.0 58.0   38.0 53.0 53.0 38.0
 Mean (SD) 83.4 (8.1) 82.4 (7.8)   84.3 (7.1) 81.5 (7.4)   81.8 (8.4) 81.9 (8.5) 83.4 (7.9) 83.4 (7.7)
 
Female (n, %) 1887 (65.8%)d 2312 (63.8%)e 0.09 148 (71.2%) 102 (58.0%) 0.007 525 (62.5%) 295 (67.4%) 528 (63.8%) 397 (61.8%)
Bilateral treatment 481 (16.8%) 670 (18.5%) 0.11 45 (21.6%) 27 (15.3%) 0.23 80 (9.4%) 42 (9.5%) 73 (8.3%) 88 (12.6%)
Study eye VA, mean letter score at index (SD) 57.5 (21.2) 58.5 (20.7) 0.025 61.9 (18.0) 61.7 (19.2) 0.91 57.8 (19.8) 57.8 (19.9) 49.1 (25.2) 51.0 (24.5)
VA letter score, n (%)
 ≥70 1098 (32.8%) 1498 (34.8%) 0.06 107 (42.3%) 89 (43.8%) 0.74 290 (31.3%) 165 (34.1%) 237 (24.8%) 193 (24.4%)
 ≤35 639 (19.1%) 777 (18.1%) 0.26 27 (10.7%) 26 (12.8%) 0.48 174 (18.8%) 93 (19.2%) 320 (33.5%) 231 (29.4%)
 
Study eye VA, mean change index to switch (SD)             −1.0 (13.9) −1.5 (15.2)    
a

Baseline VA for all treatment-naive patients (not just those with VA scores at 12 months).

b

Denominator for PED subgroup is eyes in main study. For all other cohorts, denominator is eyes that meet inclusion criteria but with no requirement for 12 months of follow-up or VA at month 12.

c

Age was collected in 5-year bands up until the maximum (90+ years). The midpoint of the band, and 92 for the highest band was used when calculating age descriptive statistics.

d

Gender not known for two patients.

e

Gender not known for five patients.